Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

Recruiting now · Not applicable

Conditions studied: Stroke, Transient Ischemic Attack (TIA)

In brief

The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.

Key facts

Study ID

NCT06943586

Run by

University of Alabama at Birmingham

People needed

200

Starts

2025-04-09

Expected to finish

2029-04-01

Last updated by the study team

2026-04-23

Who can join

Age: 18 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients 18-89 years of age
• admitted to University of Alabama at Birmingham (UAB) main hospital with symptoms or signs of minor ischemic stroke, or high risk TIA
• eligible to receive dual antiplatelet load (presented to the hospital within 66 hours of last known well)

You may not qualify if…

• diagnosis of atrial fibrillation, valvular heart disease, index stroke due to known hypercoagulability (subset of other determined etiology) or large vessel disease (culprit vessel stenosis of ≥50%)
• prescribed anticoagulation prior to stroke
• treated with intravenous thrombolysis
• treated with mechanical thrombectomy
• missing NIH Stroke Scale score

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.